Citation: | Prostate Cancer Group, Chinese Anticancer Association Genitourinary Oncology Committee. Expert Consensus of Multidisciplinary Treatment on Bone Metastasis of Prostate Cancer(Version 2020)[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 479-486. DOI: 10.3971/j.issn.1000-8578.2020.20.2020 |
[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. https://www.researchgate.net/publication/290183302_Cancer_Statistics_2016
|
[2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. https://www.researchgate.net/publication/291830601_Cancer_Statistics_in_China_2015
|
[3] |
Roudier MP, Morrissey C, True LD, et al. Histopathological assessment of prostate cancer bone osteoblastic metastases[J]. J Urol, 2008, 180(3): 1154-1160. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=fc2cdc3039afa998b192e70e40800dad
|
[4] |
McAllister SS, Weinberg RA. The Tumour-Induced Systemic Environment as a Critical Regulator of Cancer Progression and Metastasis[J]. Nat Cell Biol, 2014, 16(8): 717-727. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM25082194
|
[5] |
Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the Clonal Origin of Lethal Prostate Cancer[J]. J Clin Invest, 2013, 123(11): 4918-4922. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM24135135
|
[6] |
Robert PH, Gerald PM. Prostate Cancer: An Update[J]. CA Cancer J Clin, 1986, 36(5): 274-292. https://www.researchgate.net/publication/20063299_Prostate_Cancer_An_Update?ev=pub_cit
|
[7] |
Perez-Lopez R, Lorente D, Blackledge MD, et al. Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer[J]. Radiology, 2016, 280(1): 151-160. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a8049b990db0ecffa54a487fa47c5cb4
|
[8] |
崔炳强.全身骨显像评价前列腺癌骨转移特点及其临床应用价值[J].中国临床医学影像杂志, 2010, 21(11): 817-818. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zglcyxyxzz201011023
Cui BQ. Clinical application value of the whole body bone imaging for evaluating the characteristic of osseous metastasis in patients with prostate carcinoma[J]. Zhongguo Lin Chuang Yi Xue Ying Xiang Za Zhi, 2010, 21(11): 817-818. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zglcyxyxzz201011023
|
[9] |
那彦群, 孙颖浩, 曹登峰, 等.前列腺癌诊断治疗指南[M]//中国泌尿外科疾病诊断治疗指南手册: 2014版.北京:人民卫生出版社, 2013: 61-84.
|
[10] |
Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/CT, Tc99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer[J]. J Korean Med Sci, 2009, 24(2): 275-280. http://europepmc.org/articles/PMC2672128/
|
[11] |
Bjurlin MA, Rosenkrantz AB, Beltran LS, et al. Imaging and evaluation of patients with high-risk prostate cancer[J]. Nat Rev Urol, 2015, 12(11): 617-628. https://www.nature.com/articles/nrurol.2015.242
|
[12] |
Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases[J]. Q J Nucl Med, 2001, 45(1): 53-64. https://www.researchgate.net/publication/11886250_Rybak_LD_Rosenthal_DIRadiological_imaging_for_the_diagnosis_of_bone_metastases_Q_J_Nucl_Med_45_53-64
|
[13] |
Scutellari PN, Addonisio G, Righi R, et al. Diagnostic imaging of bone metastases[J]. Radiol Med, 2000, 100(6): 429-435. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM2973918
|
[14] |
周长友, 陈久尊, 何家维, 等.四肢骨转移瘤的影像学分析[J].实用放射学杂志, 2013, 29(11): 1823-1825, 1843. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=syfsxzz201311027
Zhou CY, Chen JZ, He JW, et al. Imaging analysis of bone metastases in the extremities[J]. Shi Yong Fang She Xue Za Zhi, 2013, 29(11): 1823-1825, 1843. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=syfsxzz201311027
|
[15] |
廖光星, 冷志星, 肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志, 2016, 40(6): 464-468. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-fsyxhyxfc201606012
Liao GX, Leng ZX, Xiao GY. Progress of imaging in the diagnosis of bone metastases of proatate cancer[J]. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi, 2016, 40(6): 464-468. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-fsyxhyxfc201606012
|
[16] |
Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43(12): 2114-2121. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e79f950ddd8018546b78d9db20cbdb1c
|
[17] |
宋伟, 李宇, 康飞, 等. 68Ga-PSMA-617 PET/CT与99Tcm-MDP骨扫描诊断前列腺癌骨转移的比较[J].中华泌尿外科杂志, 2018, 39(10): 766-770. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhmnwk201810011
Song W, Li Y, Kang F, et al. Comparison of 68Ga-PSMA-617 PET/CT and 99Tcm-MDP bone scintigraphy for bone metastases in prostate cancer[J]. Zhonghua Mi Niao Wai Ke Za Zhi, 2018, 39(10): 766-770. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhmnwk201810011
|
[18] |
Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT imaging in the management of prostate cancer[J]. Diagnostics(Basel), 2018, 8(1): 16. https://www.researchgate.net/publication/323133501_Review_of_Gallium-68_PSMA_PETCT_Imaging_in_the_Management_of_Prostate_Cancer
|
[19] |
Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, et al. Simultaneous PET/MRI vs. PET/CT in oncology. A systematic review[J]. Rev Esp Med Nucl Imagen Mol, 2016, 35(5): 306-312. https://www.researchgate.net/publication/305400572_Simultaneous_PETMRI_vs_PETCT_in_oncology_A_systematic_review?_sg=adJUvUX0Lyo00hF4EwNKCuB7p6CCFGDwEm8AAhMRFqMy0siWAgqs-3v3UUwzyqqg5A35x4WhZlrrqswQKDQQWg
|
[20] |
Al-Salama ZT. Apalutamide: first global approval[J]. Drugs, 2018, 78(6): 699-705.
|
[21] |
Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer[J]. N Engl J Med, 2018, 378(15): 1408-1418. https://pubmed.ncbi.nlm.nih.gov/29420164/
|
[22] |
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13): 1187-1197. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM22894553
|
[23] |
Fizazi K, Scher H, Molina A, et al. Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study[J]. Lancet Oncol, 2012, 13(10): 983-992. https://www.sciencedirect.com/science/article/abs/pii/S1470204512703790
|
[24] |
Charles JR, Smith MR, Fizazi K, et al. Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-Blind, Placebo-Controlled Phase 3 Study[J]. Lancet Oncol, 2015, 16(2): 152-160. https://www.sciencedirect.com/science/article/abs/pii/S1470204514712057
|
[25] |
Joaquin M, Suzanne C, Shahneen S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer[J]. N Engl J Med, 2015, 373(18): 1697-1708.
|
[26] |
Errante D, Mannucci N, Bernardi D, et al. Comment on 'Jaw avascular bone necrosis associated with long-term use of biphosphonates' [J]. Ann Oncol, 2006, 17(2): 350-352. https://www.sciencedirect.com/science/article/pii/S0923753419403633
|
[27] |
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2002, 94(19): 1458-1468. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM12359855
|
[28] |
Valcamoniaco F, Petrelli F, Ferrari L, et al. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?[J]. J Clin Oncol, 2014, 32(32): 3684-3685. https://pubmed.ncbi.nlm.nih.gov/25225432/
|
[29] |
Taneja SS. Re: Effect of Enzalutamide on Time to First Skeletal-Related Event, Pain, and Quality of Life in Men with Castration-Resistant Prostate Cancer: Results from the Randomised, Phase 3 AFFIRM Trial[J]. J Urol, 2015, 194(2): 392-393.
|
[30] |
国家中医药局办公室, 国家卫生健康委办公厅.癌症疼痛诊疗规范(2018年版)[J].全科医学临床与教育, 2019, 17(1): 4-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=qkyxlcyjy201901003
National Administration of Traditional Chinese Medicine Bureau, National Health Commission of the People's Republic of China. Standard for diagnosis and treatment of cancer pain(2018 edition)[J]. Quan Ke Yi Xue Lin Chuang Yu Jiao Yu, 2019, 17(1): 4-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=qkyxlcyjy201901003
|
[31] |
Weinfurt KP, Anstrom KJ, Castel LD, et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer[J]. Ann Oncol, 2006, 17(6): 986-989. https://www.sciencedirect.com/science/article/pii/S0923753419435679
|
[32] |
Konski A, James J, Hartsell W, et al. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases[J]. Am J Clin Oncol, 2009, 32(4): 423-428. https://pubmed.ncbi.nlm.nih.gov/19546803/
|
[33] |
Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases[J]. J Natl Cancer Inst, 2005, 97(11): 798-804.
|
[34] |
Janjan N, Lutz ST, Bedwinek JM, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology[J]. J Palliat Med, 2009, 12(5): 417-426. https://www.researchgate.net/publication/24402276_Therapeutic_Guidelines_for_the_Treatment_of_Bone_Metastasis_A_Report_from_the_American_College_of_Radiology_Appropriateness_Criteria_Expert_Panel_on_Radiation_Oncology
|
[35] |
Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review[J]. J Clin Oncol, 2007, 25(11): 1423-1436. https://pubmed.ncbi.nlm.nih.gov/17416863/
|
[36] |
Jabbari S, Gerszten PC, Ruschin M, et al. Stereotactic body radiotherapy for spinal metastases: practice guidelines, outcomes, and risks[J]. Cancer J, 2016, 22(4): 280-289. https://www.researchgate.net/publication/305497962_Stereotactic_Body_Radiotherapy_for_Spinal_Metastases_Practice_Guidelines_Outcomes_and_Risks
|
[37] |
Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease[J]. J Bone Joint Surg Am, 2009, 91(6): 1503-1516. https://pubmed.ncbi.nlm.nih.gov/19487532/
|
[38] |
Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures[J]. Clin Orthop Relat Res, 1989, (249): 256-264. doi: 10.1007%2F978-1-4471-5451-8_123
|
[39] |
Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination?[J].Cancer, 2019, 125(3): 340-352. https://www.researchgate.net/publication/329457471_Oligometastatic_prostate_cancer_Reality_or_figment_of_imagination
|
[40] |
Weichselbaum RR, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378-382. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=97e46f58c8a7c3bb5d7773f9878f9217
|
[41] |
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence:a prospective, randomized, multicenter phase Ⅱ trial[J]. J Clin Oncol, 2018, 36(5): 446-453.
|
[42] |
Satkunasivam R, Kim AE, Desai M, et al. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis[J]. J Urol, 2015, 194(2): 378-385. https://xueshu.baidu.com/usercenter/paper/show?paperid=ac9160e5666925f6e1bd5aba9a019633&site=xueshu_se
|
[43] |
Christian G, Jutta E, Christian GS, et al. Role of Radical Prostatectomy in Metastatic Prostate Cancer: Data From the Munich Cancer Registry[J]. Eur Urol, 2014, 66(3): 602-603. https://pubmed.ncbi.nlm.nih.gov/24821581/
|
[44] |
刘玉金, 杨仁杰, 张秀美, 等.骨盆骨肿瘤的介入治疗[J].介入放射学杂志, 2007, 4(16): 232-234. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jrfsxzz200704006
Liu YJ, Yang RJ, Zhang XM, et al. Therapy of pelvis bone tumor by interventional therapy[J]. Jie Ru Fang She Xue Za Zhi, 2007, 4(16): 232-234. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jrfsxzz200704006
|
[45] |
何煜, 吴春耕, 李明华, 等.经皮椎体成形术治疗颈椎转移瘤[J].介入放射学杂志, 2012, 21(3): 225-230. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jrfsxzz201203012
He Y, Wu CG, Li MH, et al. Percutaneous vertebroplasty for metastatic lesions of the cervical spine[J]. Jie Ru Fang She Xue Za Zhi, 2012, 21(3): 225-230. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jrfsxzz201203012
|
[46] |
European Parthership Against Cancer consensus group, Albreht T, Audisio R, et al. Policy statement on multidisciplinary cancer care[J]. Eur J Cancer, 2014, 50(3): 475-480. https://www.sciencedirect.com/science/article/abs/pii/S0959804913010071
|
[47] |
Hong NJL, Wright FC, Gagliardi AR, et al. Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review[J]. J Surg Oncol, 2010, 102(2): 125-134. https://pubmed.ncbi.nlm.nih.gov/20648582/
|
[1] | HU Xinyu, DONG Ruitao, LI Zhiping, DU Lin, LIU Yan. Anti-hepatocellular Carcinoma Activity and Related Mechanism of Apigenin-7-O-Glucoside[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 248-254. DOI: 10.3971/j.issn.1000-8578.2021.20.0796 |
[2] | LIU Wen, LI Feifei, ZHONG Minggui, LIU Yakun, FANG Haoshu, WANG Siying. TEC Expresses Highly in Hepatocellular Carcinoma and Is Involved in Drug Resistance[J]. Cancer Research on Prevention and Treatment, 2018, 45(9): 660-665. DOI: 10.3971/j.issn.1000-8578.2018.18.0107 |
[3] | LIU Huihui, JIANG Liangqian, WANG Yujuan, LIU Guoxiang, JI Huanhuan, REN Junyi, LI Bing. Application Status of C-phycocyanin in Anti-tumor[J]. Cancer Research on Prevention and Treatment, 2018, 45(6): 420-424. DOI: 10.3971/j.issn.1000-8578.2018.17.1464 |
[4] | WANG Yongqiang, YE Ting, LIU Jinbo. DNA Methylation Profile of Tumor Suppressor Genes in Diagnosis of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1330-1334. DOI: 10.3971/j.issn.1000-8578.2014.12.017 |
[5] | YI Yanmei, DU Jun, CHEN Dong, TANG Wenying. Anti-tumor Effect of Polypeptide Vaccine FAPτ from Fibroblast Activation Protein &alpha[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 294-296. DOI: 10.3971/j.issn.1000-8578.2014.04.002 |
[6] | Dong Zhongyi, Zeng Qin, Wang Jian, Liang Jiyun, Cao Chuanhui, Huang Zhiyong, Wu Dehua. Effect of Primary Tumor Location on Postoperative Recurrence for Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(05): 542-546. DOI: 10.3971/j.issn.1000-8578.2012.05.012 |
[7] | YANG Jian-lin, FAN Xiao-hui. Cytotoxic Activities ofNOV D817on Hepatocellular Carcinoma Cells in Vitro and Their Possible Mechanism[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 305-308. DOI: 10.3971/j.issn.1000-8578.2010.03.017 |
[8] | ZHANG Xi-guo, SHI Jian-guo, LIU Yan-fang, YAN Qing-guo. Anti-hepatocarcinoma Therapeutical Effect of Tumor Special CTL Activated by Two Kind of Dendritic Cells in Nude Mice[J]. Cancer Research on Prevention and Treatment, 2006, 33(07): 493-495,. DOI: 10.3971/j.issn.1000-8578.2291 |
[9] | REN Jing, FENG Guo-nan, WANG Min-wei, SUN Li-xin. The Primary Study on the Anti-tumor Effect of Total Saponin of Solanum Lyratum Thunb[J]. Cancer Research on Prevention and Treatment, 2006, 33(04): 262-264. DOI: 10.3971/j.issn.1000-8578.3382 |
[10] | ZHANG Li-ming, YIN Mu-quan, HE Qian, et al. The contrast of telomerase activity between cytoplasmic and nuclear extracts of hepatocellular carcinoma samples[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 7-8. DOI: 10.3971/j.issn.1000-8578.106 |